(CMPX) Compass Therapeutics - Overview
Stock: Trocimig, CTX-471, CTX-8371, CTX-10726
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 74.4% |
| Relative Tail Risk | -6.49% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.14 |
| Alpha | 75.21 |
| Character TTM | |
|---|---|
| Beta | 1.177 |
| Beta Downside | 1.560 |
| Drawdowns 3y | |
|---|---|
| Max DD | 79.90% |
| CAGR/Max DD | 0.25 |
Description: CMPX Compass Therapeutics December 29, 2025
Compass Therapeutics (NASDAQ:CMPX) is a Boston-based, clinical-stage biotech that concentrates on antibody-based oncology therapies. Its lead candidates are tove-cimig, a DLL4/VEGF-A bispecific designed to shut down tumor angiogenesis; CTX-471, an IgG4 agonist of the T-cell co-stimulatory receptor CD137; and CTX-8371, a PD-1/PD-L1 bispecific checkpoint inhibitor. The company also maintains a broader pipeline of bispecifics targeting VEGF-A, PD-1 and other immune-modulatory pathways.
Key operational metrics (Q2 2025 filing) show ~ $68 million in cash and equivalents, a net loss of $22 million for the quarter, and an R&D spend of $15 million, reflecting its heavy investment in early-stage trials. The oncology biotech sector is benefiting from a projected $200 billion global market for bispecific antibodies by 2030, while recent FDA approvals of similar agents (e.g., tebentafusp, amivantamab) have accelerated investor interest and partnership opportunities. Compass recently entered a research collaboration with a major pharma partner to co-develop its VEGF-IO bispecific platform, potentially de-risking later-stage development and providing non-dilutive funding.
For a deeper, data-driven view of CMPX’s valuation dynamics, you might explore the analyst dashboards on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 1.0
| Net Income: -65.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.19 > 0.02 and ΔFCF/TA 12.76 > 1.0 |
| NWC/Revenue: 24.6k% < 20% (prev 3701 %; Δ 20.9k% < -1%) |
| CFO/TA -0.19 > 3% & CFO -45.1m > Net Income -65.8m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 17.82 > 1.5 & < 3 |
| Outstanding Shares: last quarter (138.3m) vs 12m ago 0.50% < -2% |
| Gross Margin: 56.82% > 18% (prev 0.75%; Δ 5608 % > 0.5%) |
| Asset Turnover: 0.45% > 50% (prev 2.48%; Δ -2.03% > 0%) |
| Interest Coverage Ratio: -17.21 > 6 (EBITDA TTM -68.8m / Interest Expense TTM -4.06m) |
Altman Z'' -15.00
| A: 0.90 (Total Current Assets 221.1m - Total Current Liabilities 12.4m) / Total Assets 231.3m |
| B: -1.80 (Retained Earnings -415.5m / Total Assets 231.3m) |
| C: -0.37 (EBIT TTM -69.9m / Avg Total Assets 190.2m) |
| D: -19.18 (Book Value of Equity -415.1m / Total Liabilities 21.6m) |
| Altman-Z'' Score: -22.54 = D |
What is the price of CMPX shares?
Over the past week, the price has changed by +1.87%, over one month by +32.79%, over three months by +63.00% and over the past year by +86.29%.
Is CMPX a buy, sell or hold?
- StrongBuy: 7
- Buy: 2
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the CMPX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 13.2 | 102.9% |
| Analysts Target Price | 13.2 | 102.9% |
| ValueRay Target Price | 7.3 | 11.8% |
CMPX Fundamental Data Overview February 03, 2026
P/B = 5.4136
Revenue TTM = 850.0k USD
EBIT TTM = -69.9m USD
EBITDA TTM = -68.8m USD
Long Term Debt = 9.87m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 633.0k USD (from shortTermDebt, last quarter)
Debt = 9.87m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -36.3m USD (from netDebt column, last quarter)
Enterprise Value = 928.3m USD (1.14b + Debt 9.87m - CCE 219.9m)
Interest Coverage Ratio = -17.21 (Ebit TTM -69.9m / Interest Expense TTM -4.06m)
EV/FCF = -20.59x (Enterprise Value 928.3m / FCF TTM -45.1m)
FCF Yield = -4.86% (FCF TTM -45.1m / Enterprise Value 928.3m)
FCF Margin = -5303 % (FCF TTM -45.1m / Revenue TTM 850.0k)
Net Margin = -7742 % (Net Income TTM -65.8m / Revenue TTM 850.0k)
Gross Margin = 56.82% ((Revenue TTM 850.0k - Cost of Revenue TTM 367.0k) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 4.01 (Enterprise Value 928.3m / Total Assets 231.3m)
Interest Expense / Debt = 18.99% (Interest Expense 1.87m / Debt 9.87m)
Taxrate = 21.0% (US default 21%)
NOPAT = -55.2m (EBIT -69.9m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 17.82 (Total Current Assets 221.1m / Total Current Liabilities 12.4m)
Debt / Equity = 0.05 (Debt 9.87m / totalStockholderEquity, last quarter 209.6m)
Debt / EBITDA = 0.53 (negative EBITDA) (Net Debt -36.3m / EBITDA -68.8m)
Debt / FCF = 0.81 (negative FCF - burning cash) (Net Debt -36.3m / FCF TTM -45.1m)
Total Stockholder Equity = 134.6m (last 4 quarters mean from totalStockholderEquity)
RoA = -34.60% (Net Income -65.8m / Total Assets 231.3m)
RoE = -48.90% (Net Income TTM -65.8m / Total Stockholder Equity 134.6m)
RoCE = -48.37% (EBIT -69.9m / Capital Employed (Equity 134.6m + L.T.Debt 9.87m))
RoIC = -41.01% (negative operating profit) (NOPAT -55.2m / Invested Capital 134.6m)
WACC = 10.29% (E(1.14b)/V(1.15b) * Re(10.25%) + D(9.87m)/V(1.15b) * Rd(18.99%) * (1-Tc(0.21)))
Discount Rate = 10.25% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 4.07%
Fair Price DCF = unknown (Cash Flow -45.1m)
EPS Correlation: 7.14 | EPS CAGR: 18.53% | SUE: 3.18 | # QB: 2
Revenue Correlation: 8.37 | Revenue CAGR: 0.0% | SUE: 0.0 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.10 | Chg30d=+0.003 | Revisions Net=+1 | Analysts=8
EPS next Year (2026-12-31): EPS=-0.41 | Chg30d=+0.005 | Revisions Net=+1 | Growth EPS=+1.0% | Growth Revenue=+0.0%